Clinical trial · Interventional
Application of Telemedicine to the Management of Aggressive Lymphomas
Application of Telemedicine to the Management of Aggressive Lymphomas: a Regional Comparative Study
NCT03336138CI-TRIAL-00098976AMAcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that the AMA support should allow a significant improvement of the RDI compared to the control group and thus impact the duration without progression. The study covers 350 patients recruited from 10 regional centers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AMA (Assistance for ambulatory patients) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- AMA group
- description
- Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
- interventionNames
- Other: AMA (Assistance for ambulatory patients)
- type
- NO_INTERVENTION
- label
- Control group
- description
- Patient with standard follow-up with no specific assistance for ambulatory patients
Primary outcomes (1)
- measure
- dose-relative intensity (RDI)
- timeFrame
- through study completion, an average of 2 years
- description
- reduction of RDI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started * a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP). * Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible. * accepting the study Exclusion Criteria: * Patient with another type of lymphoma (including transformed follicular forms) * Patient having already started his treatment. * Life expectancy \<3 months. * Carcinologic history * Serum positive for HIV or hepatitis B virus (HBV).
References
Publications (2)
- RESULTLamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Recher C, Nogaro JC, Despas F, Laurent G, Delpierre C. The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study. BMC Health Serv Res. 2016 Aug 2;16(a):336. doi: 10.1186/s12913-016-1553-9. PMID 27485349
- RESULTBorel C, Lamy S, Compaci G, Recher C, Jeanneau P, Nogaro JC, Bauvin E, Despas F, Delpierre C, Laurent G. A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. BMC Cancer. 2015 Apr 15;15:288. doi: 10.1186/s12885-015-1287-9. PMID 25884669